[Federal Register: May 10, 2004 (Volume 69, Number 90)]
[Notices]
[Page 25904-25909]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr10my04-61]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Program Announcement 04132]
Organ Transplant Infection Detection and Prevention Program
Announcement Type: New.
Funding Opportunity Number: 04132.
Catalog of Federal Domestic Assistance Number: 93.283.
Key Dates: Letter of Intent Deadline: May 25, 2004.
Application Deadline: June 24, 2004.
Executive Summary: The Organ Transplant Infection Detection and
Prevention (OTIP) Program will rapidly assess the public health impact
of new infection prevention programs in organ transplant recipients
through a program of sentinel surveillance, applied research and
collaborative prevention studies. Such assessments would be the basis
for national prevention programs to eliminate or minimize invasive
fungal disease and related mortality in this population. In addition,
the program would create a repository of clinically relevant isolates
and specimens with relevant patient information from which applied
research can further scientific knowledge regarding novel diagnostics
and emerging antimicrobial resistance.
I. Funding Opportunity Description
Authority: This program is authorized under the Public Health
Service Act, section 317(k)(2) [42 U.S.C. 247b(k)(2)].
Purpose
The purpose of the OTIP Program is to support organ transplant
centers participating in existing surveillance or research networks to
develop a consortium of centers of excellence in surveillance,
infection prevention, and applied public health research involving
solid organ and stem-cell transplant recipients. The OTIP should be
designed to develop, implement, and evaluate effectiveness of
epidemiologic-based strategies to reduce infectious outcomes among
organ-transplant recipients. Examples of existing networks include The
Centers for Disease Control and Prevention (CDC) Program of
Surveillance for Invasive Fungal Infections in Transplant Recipients
(TransNet), CDC's Prevention Epicenter Program, and National Marrow
Donor Program's Infection Pilot Project.
The goals of the OTIP program are: (1) Support activities at
participating transplant centers for enhanced surveillance for fungal
infections during the post-transplant period, using similar methods and
intensity of case-ascertainment, with development of valid, useful,
simple surveillance methods for exportation to non-program transplant
centers; (2) support activities at participating transplant centers
related to epidemiologic assessments and improved descriptions of
established infectious syndromes through a repository of clinical
samples (e.g., serial serum, bronchial-alveolar lavage) and
identification of novel risk factors for disease (e.g., role of home
environment in late onset aspergillosis); and (3) be a national
resource for assessing effectiveness of new infection prevention
strategies in this population. As invasive fungal infections represent
the highest infection-related mortality in this population, initial
activities should focus exclusively on these pathogens; other pathogens
may be incorporated into later years of the program.
This program addresses the ``Healthy People 2010'' focus area(s) of
Immunization and Infectious Diseases. For the conference copy of
``Healthy People 2010'', visit the Internet site: http://www.health.gov/healthypeople
.
Measurable outcomes of the program will be in alignment with the
performance goal for the National Center for Infectious Diseases
(NCID): To protect Americans from infectious diseases by planning,
directing, and coordinating a national program to improve the
identification, investigation, diagnosis, prevention, and control of
infectious diseases in the United States and throughout the world.
Research Objectives
Roughly 18,000 bone marrow/stem cell transplants (SCCs) and over
23,000 solid organ transplants (SOTs) are performed annually within the
U.S. Approximately 10-15 percent of recipients will develop an invasive
fungal infection post-transplant. In this population, the mortality of
invasive aspergillosis can exceed 90 percent; the mortality of invasive
candidiasis is approximately 40 percent. The OTIP Program will provide
the foundation for applied research designed to fulfill current gaps in
scientific knowledge regarding surveillance and prevention of invasive
fungal infections in the post-transplant period. Such knowledge
[[Page 25905]]
includes identification of an efficient and valid surveillance
methodology, understanding the utility of novel diagnostics used to
detect fungal, bacterial, or viral pathogens, and identification of
modifiable risk factors for disease and effective prevention tools. In
order to gain this knowledge, the objectives of the OTIP Program
should: (1) Identify and validate efficient surveillance methodology
exportable to non-program centers; (2) identify modifiable
environmental or other factors extrinsic to the transplant patient
(e.g., device-specific factors, environmental exposures) which can be
addressed to prevent infectious diseases in the post-transplant period;
(3) describe the pathogen and infection characteristics of common
infections among patients in the post-transplant period; and (4)
through knowledge gained from (1)-(3), demonstrate the efficacy of
novel prevention measures in reducing post-transplant infectious
complications and associated mortality. The types of experimental
approaches that may be used to achieve the goals of the program
include: development of the ``gold standard'' approach to surveillance
for invasive fungal infections in the post-transplant population and
validate efficacy of an exportable surveillance methodology;
prospective case-control studies for common invasive fungal infections,
such as late-onset aspergillosis, including targeted environmental
sampling; establishment of a serum, urine, and/or bronchial-alveolar
lavage specimen repository for determining effectiveness of novel
diagnostics for infections (e.g., fungal, viral); and using risk-
adjusted infection-related outcomes, ascertain the effectiveness of
novel prevention program in reducing disease (prophylaxis strategies,
educational interventions). Because organ-transplant patients are at
risk for prolonged periods post-transplant (i.e., several years), these
activities must be conducted within a specialized network of
collaborating centers capable of long-term continuity of care of these
patients (i.e., over one year). The operational organization of The
OTIP Program must include two or more consortiums of two to four
transplant centers with sufficient infrastructure (e.g., surveillance
staff and laboratory support) supported by the consortium leaders to
accomplish the objectives.
Activities
Awardee activities for this program are as follows:
1. Establish a consortium of at least two solid-organ and/or stem-
cell transplant centers consistent with the purpose of the OTIP
Program.
2. Collaborate with other OTIP Program sites and CDC to operate as
the OTIP Program, and facilitate and oversee implementation of core
activities (e.g., activities to be done at all centers participating in
the OTIP Program). This includes providing resources to investigators
at centers participating in the applicant's consortium to support OTIP
Program activities. Activities may be prioritized and time-phased. Core
activities include:
a. Perform ``gold standard'' surveillance for invasive fungal
infections incorporating the following elements:
i. Active-surveillance using standardized diagnostic evaluations
and follow-up of patients among participating sites (e.g., proper
training of surveillance personnel, collection and evaluation of fungal
isolates).
ii. Design and maintain an aggregate database (e.g., standardized
protocol) recording both events and relevant patient data from all
organ-transplant recipients to maintain a valid risk-adjusted
surveillance system among all transplant sites.
iii. Optionally, include time-phased plans to incorporate other
infectious outcomes.
iv. Optionally, include time-phased plans to explore utility of
electronic capture of data elements and/or utilization of other
existing data systems related to transplant recipients.
b. Epidemiologic assessments to identify modifiable risk factors,
focusing on those extrinsic to the patient, for invasive fungal disease
in the post-transplant period.
c. Development of a repository of clinical samples and relevant
clinical data for assessment of novel diagnostics or pathogen
discovery, and outline plans to facilitate making isolates available to
a wider public health research community.
d. Develop plans and implement OTIP Network study to assess novel
prevention strategies based on (a)-(c) above.
3. Participate in management, analysis, and interpretation data,
publish and disseminate important medical and public health information
stemming from OTIP Program activities in collaboration with all OTIP
Program sites.
4. Monitor and evaluate scientific and operational accomplishments
and progress in achieving the purpose of this program.
In a cooperative agreement, CDC staff is substantially involved in
the program activities, above and beyond routine grant monitoring.
CDC Activities for this program are as follows:
1. The CDC Staff will have substantial scientific-programmatic
involvement during the conduct of these activities, through technical
assistance, advice and coordination above and beyond normal program
stewardship for grants, including participation in data collection,
analysis, interpretation of data, and presentation of research
findings.
2. The CDC Staff will facilitate operations of the program through
maintenance of a Steering Committee, and coordinate the dissemination
of information to Principal Investigators and others.
3. As requested, will serve as a reference laboratory and receive,
process, store, and perform evaluation of clinical (e.g., serum
repository) or environmental specimens, perform molecular epidemiologic
studies, evaluate novel diagnostics, perform confirmatory testing and/
or susceptibility testing on fungal isolates obtained in OTIP projects.
4. As requested, serve as a resource for and support data
management, bio-statistical and epidemiologic analysis.
5. Assist in the development of surveillance and research protocols
for IRB review by all cooperating institutions participating in the
research project, as well as CDC approval.
Collaborative Activities for the Program are as follows:
1. Timing, protocol development, and implementation strategy of
core activities of the OTIP Program will be decided by Steering
Committee consisting of Principal Investigators of each OTIP Program
cooperative agreement, CDC, and other select representatives (e.g.,
participating transplant centers, professional society). The purpose of
the Steering Committee is to share scientific information, assess
scientific progress, identify new research opportunities, and decide on
major aspects of program operations. Decisions will be made by a
majority vote of a quorum, with an attempt for consensus when possible.
The Steering Committee will convene through both telephone conference
and in person.
II. Award Information
Type of Award: Cooperative Agreement.
CDC involvement in this program is listed in the Activities Section
above.
Fiscal Year Funds: 2004.
Approximate Total Funding: $350,000.
[[Page 25906]]
Approximate Number of Awards: One to two.
Approximate Average Award: $175,000 (This amount is for the first
12-month budget period, and includes both direct and indirect costs).
Floor of Award Range: None.
Ceiling of Award Range: $200,000.
Anticipated Award Date: August 30, 2004.
Budget Period Length: 12 months.
Project Period Length: Five years.
Throughout the project period, CDC's commitment to continuation of
awards will be conditioned on the availability of funds, evidence of
satisfactory progress by the recipient (as documented in required
reports), and the determination that continued funding is in the best
interest of the Federal Government.
III. Eligibility Information
III.1. Eligible Applicants
Applications may be submitted by public and private nonprofit
organizations, such as:
Public nonprofit organizations
Private nonprofit organizations
Universities
Research institutions
Hospitals
III.2. Cost Sharing or Matching
Matching funds are not required for this program.
III.3. Other
If you request a funding amount greater than the ceiling of the
award range, your application will be considered non-responsive, and
will not be entered into the review process. You will be notified that
your application did not meet the submission requirements.
If your application is incomplete or non-responsive to the
requirements listed in this section, it will not be entered into the
review process. You will be notified that your application did not meet
submission requirements.
Other eligibility requirements include: (1) Identification of
consortium of transplant centers which in aggregate perform on average
1000 transplants per year and may include a combination of solid-organ
and stem-cell transplants; (2) appropriate diagnostic evaluations are
performed on patients post-transplant to ascertain etiology of the
illness post-transplantation; (3) participating centers have capacity
to perform intensive surveillance, epidemiologic assessments, and
facilities to ensure efficient processing of patient specimens.
Documentation of eligibility can be accomplished by including the
following: (1) Infection control or other surveillance data (e.g., from
sites currently participating in surveillance networks) from applicants
and proposed collaborating sites describing total number of
transplants, type of transplants, and percent of transplant patients
developing invasive fungal infections; (2) outline of current practice
in documenting etiology of post-transplant illness in this population;
and (3) a bulleted list of titles of at least one, but no more than
five, current or recent epidemiologic and/or prevention research
projects or studies undertaken from each proposed collaborating sites
(e.g., part of quality improvement projects, infection control, multi-
site or single-site epidemiologic studies).
The limitation on eligibility is justified by the essential need to
have sufficient numbers of transplanted individuals and sufficient
disease incidence to adequately perform studies to achieve objectives
of the OTIP Program. In addition, centers must currently practice a
standard of care that will maximize identification of infecting
pathogens in this population. Finally, demonstration of past
performance in conducting epidemiologic investigation and prevention
research will ensure applicants ability to perform objectives.
Individuals Eligible to Become Principal Investigators: Any
individual with the skills, knowledge, and resources necessary to carry
out the proposed research is invited to work with their institution to
develop an application for support. Individuals from underrepresented
racial and ethnic groups as well as individuals with disabilities are
always encouraged to apply for CDC programs.
Note: Title 2 of the United States Code section 1611 states that
an organization described in section 501(c)(4) of the Internal
Revenue Code that engages in lobbying activities is not eligible to
receive Federal funds constituting an award, grant, or loan.
IV. Application and Submission Information
IV.1. Address To Request Application Package
To apply for this funding opportunity, use application form PHS 398
(OMB number 0925-0001 rev. 5/2001). Forms and instructions are
available in an interactive format on the CDC Web site, at the
following Internet address: http://www.cdc.gov/od/pgo/forminfo.htm.
Forms and instructions are also available in an interactive format
on the National Institutes of Health (NIH) Web site at the following
Internet address: http://grants.nih.gov/grants/funding/phs398/phs398.html
.
If you do not have access to the Internet, or if you have
difficulty accessing the forms on-line, you may contact the CDC
Procurement and Grants Office Technical Information Management Section
(PGO-TIM) staff at: 770-488-2700. Application forms can be mailed to
you.
IV.2. Content and Form of Application Submission
Letter of Intent (LOI): Your LOI must be written in the following
format:
Maximum number of pages: One
Font size: 12-point unreduced
Single spaced
Paper size: 8.5 by 11 inches
Page margin size: One inch
Printed only on one side of page
Written in plain language, avoid jargon
Your LOI must contain the following information:
Descriptive title of the proposed research
Name, address, e-mail address, and telephone number of the
Principal Investigator
Names of other key personnel
Number and title of this Program Announcement (PA)
Application: Follow the PHS 398 application instructions for
content and formatting of your application. For further assistance with
the PHS 398 application form, contact PGO-TIM staff at 770-488-2700, or
contact GrantsInfo, Telephone (301) 435-0714, E-mail:
GrantsInfo@nih.gov.
Your research plan should address activities to be conducted over
the entire project period.
You are required to have a Dun and Bradstreet Data Universal
Numbering System (DUNS) number to apply for a grant or cooperative
agreement from the Federal government. Your DUNS number must be entered
on line 11 of the face page of the PHS 398 application form. The DUNS
number is a nine-digit identification number, which uniquely identifies
business entities. Obtaining a DUNS number is easy and there is no
charge. To obtain a DUNS number, access http://www.dunandbradstreet.com
or call 1-866-705-5711. For more information, see the CDC Web site at:
http://www.cdc.gov/od/pgo/funding/pubcommt.htm.
This PA uses just-in-time concepts. It also uses the modular
budgeting as well as non-modular budgeting formats. See: http://grants.nih.gov/grants/funding/modular/modular.htm
for additional
guidance on modular budgets.
[[Page 25907]]
Specifically, if you are submitting an application with direct costs in
each year of $250,000 or less, use the modular budget format.
Otherwise, follow the instructions for non-modular budget research
grant applications.
Additional requirements that may require you to submit additional
documentation with your application are listed in section ``VI.2.
Administrative and National Policy Requirements.''
IV.3. Submission Dates and Times
LOI Deadline Date: May 25, 2004.
CDC requests that you send a LOI if you intend to apply for this
program. Although the LOI is not required, not binding, and does not
enter into the review of your subsequent application, the LOI will be
used to gauge the level of interest in this program, and to allow CDC
to plan the application review.
Application Deadline Date: June 21, 2004.
Explanation of Deadlines: Applications must be received in the CDC
Procurement and Grants Office by 4 p.m. eastern time on the deadline
date. If you send your application by the United States Postal Service
or commercial delivery service, you must ensure that the carrier will
be able to guarantee delivery of the application by the closing date
and time. If CDC receives your application after closing due to: (1)
Carrier error, when the carrier accepted the package with a guarantee
for delivery by the closing date and time, or (2) significant weather
delays or natural disasters, you will be given the opportunity to
submit documentation of the carriers guarantee. If the documentation
verifies a carrier problem, CDC will consider the application as having
been received by the deadline.
This announcement is the definitive guide on application submission
address and deadline. It supersedes information provided in the
application instructions. If your application does not meet the
deadline above, it will not be eligible for review, and will be
discarded. You will be notified that your application did not meet the
submission requirements.
CDC will not notify you upon receipt of your application. If you
have a question about the receipt of your application, first contact
your courier. If you still have a question, contact the PGO-TIM staff
at: 770-488-2700. Before calling, please wait two to three days after
the application deadline. This will allow time for applications to be
processed and logged.
IV.4. Intergovernmental Review of Applications
Your application is subject to Intergovernmental Review of Federal
Programs, as governed by Executive Order (EO) 12372. This order sets up
a system for state and local governmental review of proposed federal
assistance applications. You should contact your state single point of
contact (SPOC) as early as possible to alert the SPOC to prospective
applications, and to receive instructions on your state's process.
Click on the following link to get the current SPOC list: http://www.whitehouse.gov/omb/grants/spoc.html
.
IV.5. Funding Restrictions
Restrictions, which must be taken into account while writing your
budget, are as follows: a separate budget should be included for each
proposed collaborating center. Within each budget, include line items,
if appropriate, for specific funds addressing each respective recipient
activity. Funds requested related to activities that are time-specific
(e.g., risk factor study in year 2-3, adding repository of clinical
specimens in year 2, adding food borne pathogen surveillance in year 3)
should appear as line items in the appropriate years only. Cost for
semi-annual steering group meetings, training sessions, or related
travel/meeting expenses should be separated from other travel.
If you are requesting indirect costs in your budget, you must
include a copy of your indirect cost rate agreement. If your indirect
cost rate is a provisional rate, the agreement should be less than 12
months of age.
Awards will not allow reimbursement of pre-award costs.
IV.6. Other Submission Requirements
LOI Submission Address: Submit your LOI by express mail, delivery
service, fax, or e-mail to: Barbara Stewart, Public Health Analyst,
Centers for Disease Control and Prevention, National Center for
Infectious Diseases, 1600 Clifton Rd., MS C19, Atlanta, GA 30333, (404)
639-0044, (404) 639-2469, bstewart@cdc.gov.
Application Submission Address: Submit the original and five hard
copies of your application by mail or express delivery service to:
Technical Information Management-PA 04132, CDC Procurement and
Grants Office, 2920 Brandywine Road, Atlanta, GA 30341.
Applications may not be submitted electronically at this time.
V. Application Review Information
V.1. Criteria
You are required to provide measures of effectiveness that will
demonstrate the accomplishment of the various identified objectives of
the cooperative agreement. Measures of effectiveness must relate to the
performance goals stated in the ``Purpose'' section of this
announcement. Measures must be objective and quantitative, and must
measure the intended outcome. These measures of effectiveness must be
submitted with the application and will be an element of evaluation.
The goals of CDC-supported research are to advance the
understanding of biological systems, improve the control and prevention
of disease and injury, and enhance health. In the written comments,
reviewers will be asked to evaluate the application in order to judge
the likelihood that the proposed research will have a substantial
impact on the pursuit of these goals.
The scientific review group will address and consider each of the
following criteria in assigning the application's overall score,
weighting them as appropriate for each application. The application
does not need to be strong in all categories to be judged likely to
have major scientific impact and thus deserve a high priority score.
For example, an investigator may propose to carry out important work
that by its nature is not innovative, but is essential to move a field
forward.
The criteria are as follows:
Significance: Does this study address an important problem? If the
aims of the application are achieved, how will scientific knowledge be
advanced? What will be the effect of these studies on the concepts or
methods that drive this field?
Approach: Are the conceptual framework, design, methods, and
analyses adequately developed, well-integrated, and appropriate to the
aims of the project? Does the applicant acknowledge potential problem
areas and consider alternative tactics? Does the selection of
transplant centers participating in the consortium allow for sufficient
diversity or number of transplants to ensure success of the program?
Are any unique features of the consortium that ensure success with the
multi-site nature of the activities? If transplants of only a limited
type (e.g., stem-cell only) are represented by the applicant's
consortium, will such a homogenous patient mix result in improved
scientific productivity and ability to accomplish objectives of the
OTIP Program to justify the approach?
[[Page 25908]]
Innovation: Does the project employ novel concepts, approaches or
methods? Are the aims original and innovative? Does the project
challenge existing paradigms or develop new methodologies or
technologies?
Investigator: Is the investigator appropriately trained and well
suited to carry out this work? Is the work proposed appropriate to the
experience level of the principal investigator and other researchers
(if any)?
Environment: Does the scientific environment in which the work will
be done contribute to the probability of success? Do the proposed
experiments take advantage of unique features of the scientific
environment or employ useful collaborative arrangements? Is there
evidence of institutional support? Does the proposed consortium of
transplant centers build on any existing surveillance and public health
research infrastructure to ensure success?
Additional Review Criteria: In addition to the above criteria, the
following items will be considered in the determination of scientific
merit and priority score:
1. Program priorities include activities focused on invasive fungal
infections. Bacterial and Viral pathogens should be phased in over time
if funding becomes available.
2. Proposed transplant centers participating in consortium should
maximize use of scarce resources (e.g., utilizing same surveillance
personnel for both stem-cell and solid-organ transplant patients if
both transplant populations are participating, incorporation of some
activities into routine infection control activities).
3. Degree of commitment expressed in letters of support from all
essential personnel or departments from proposed transplant centers to
be in consortium (e.g., infection control, clinical microbiology,
transplantation division).
Protection of Human Subjects from Research Risks: Does the
application adequately address the requirements of title 45 CFR part 46
for the protection of human subjects? This will not be scored; however,
an application can be disapproved if the research risks are
sufficiently serious and protection against risks is so inadequate as
to make the entire application unacceptable.
Inclusion of Women and Minorities in Research: Does the application
adequately address the CDC Policy requirements regarding the inclusion
of women, ethnic, and racial groups in the proposed research? This
includes: (1) The proposed plan for the inclusion of both sexes and
racial and ethnic minority populations for appropriate representation;
(2) The proposed justification when representation is limited or
absent; (3) A statement as to whether the design of the study is
adequate to measure differences when warranted; and (4) A statement as
to whether the plans for recruitment and outreach for study
participants include the process of establishing partnerships with
community(ies) and recognition of mutual benefits.
Budget: The reasonableness of the proposed budget and the requested
period of support in relation to the proposed research.
V.2. Review and Selection Process
Applications will be reviewed for completeness by the Procurement
and Grants Office (PGO) and for responsiveness by NCID. Incomplete
applications and applications that are non-responsive to the
eligibility criteria will not advance through the review process.
Applicants will be notified that their application did not meet
submission requirements.
Applications that are complete and responsive to the PA will be
evaluated for scientific and technical merit by an appropriate peer
review group or charter study section convened by NCID in accordance
with the review criteria listed above. As part of the initial merit
review, all applications may:
Undergo a process in which only those applications deemed
to have the highest scientific merit, generally the top half of the
applications under review, will be discussed and assigned a priority
score.
Receive a written critique.
Receive a second level review by the Mycotic Diseases
Branch.
Award Criteria: Criteria that will be used to make award decisions
include:
Scientific merit (as determined by peer review).
Availability of funds.
Programmatic priorities.
VI. Award Administration Information
VI.1. Award Notices
Successful applicants will receive a Notice of Grant Award (NGA)
from the CDC Procurement and Grants Office. The NGA shall be the only
binding, authorizing document between the recipient and CDC. The NGA
will be signed by an authorized Grants Management Officer, and mailed
to the recipient fiscal officer identified in the application.
Unsuccessful applicants will receive notification of the results of
the application review by mail.
VI.2. Administrative and National Policy Requirements
45 CFR Part 74 and Part 92
For more information on the Code of Federal Regulations, see the
National Archives and Records Administration at the following Internet
address: http://www.access.gpo.gov/nara/cfr/cfr-table-search.html.
The following additional requirements apply to this project:
AR-1 Human Subjects Requirements
AR-2 Requirements for Inclusion of Women and Racial and Ethnic
Minorities in Research
AR-3 Animal Subjects Requirements
AR-6 Patient Care
AR-7 Executive Order 12372
AR-9 Paperwork Reduction Act Requirements
AR-10 Smoke-Free Workplace Requirements
AR-11 Healthy People 2010
AR-12 Lobbying Restrictions
AR-15 Proof of Non-Profit Status
AR-22 Research Integrity
AR-24 Health Insurance Portability and Accountability Act
Requirements
Additional information on these requirements can be found on the
CDC Web site at the following Internet address: http://www.cdc.gov/od/pgo/funding/ARs.htm
.
VI.3. Reporting
You must provide CDC with an original, plus two hard copies of the
following reports:
1. Interim progress report, (use form PHS 2590, OMB Number 0925-
0001, rev. 5/2001 as posted on the CDC Web site) no less than 90 days
before the end of the budget period. The progress report will serve as
your non-competing continuation application, and must contain the
following elements:
a. Current Budget Period Activities Objectives.
b. Current Budget Period Financial Progress.
c. New Budget Period Program Proposed Activity Objectives.
d. Budget.
e. Additional Requested Information.
f. Measures of Effectiveness.
2. Financial status report and annual progress report, no more than
90 days after the end of the budget period.
3. Final financial and performance reports, no more than 90 days
after the end of the project period.
These reports must be mailed to the Grants Management Specialist
listed in the ``Agency Contacts'' section of this announcement.
[[Page 25909]]
VII. Agency Contacts
For general questions about this announcement, contact: Technical
Information Management Section, CDC Procurement and Grants Office, 2920
Brandywine Road, Atlanta, GA 30341, Telephone: 770-488-2700.
For scientific/research issues, contact: Dr. Mary Lerchen,
Extramural Program Official, CDC, National Center for Infectious
Diseases, 1600 Clifton Road, NE., Mailstop: C-19, Atlanta, GA 30333,
Telephone: 404-639-0043, E-mail: mlerchen@cdc.gov.
For questions about peer review, contact: Barbara Stewart, CDC,
National Center for Infectious Diseases, 1600 Clifton Road, NE.,
Mailstop: C-19, Atlanta, GA 30333, Telephone: 404-639-0044, E-mail:
bstewart@cdc.gov.
For financial, grants management, or budget assistance, contact:
Sharon Robertson, Grants Management Specialist, CDC Procurement and
Grants Office, 2920 Brandywine Road, Atlanta, GA 30341, Telephone:770-
488-2748, E-mail: sqr2@cdc.gov.
VIII. Other Information
None.
William P. Nichols,
Acting Director, Procurement and Grants Office, Centers for Disease
Control and Prevention.
[FR Doc. 04-10535 Filed 5-7-04; 8:45 am]
BILLING CODE 4163-18-P